drug_type
RELEVANT_DRUG
intervention_type
Biological; adoptive cell therapy (CAR-T)
drug_description
Autologous 4th-generation chimeric antigen receptor T-cell therapy engineered to target glypican-3 (GPC3) on hepatocellular carcinoma cells; administered intravenously. Antigen engagement triggers CAR signaling leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor that binds glypican-3 (GPC3) on hepatocellular carcinoma cells; antigen engagement triggers CAR signaling (CD3ζ with costimulatory domains) leading to T‑cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of GPC3-positive tumor cells.
drug_name
CBG166 (anti-GPC3 CAR-T)
nct_id_drug_ref
NCT06461624